Evidence map›Paper›PMID 33007490›Full record

ArticleActa biomaterialia2020

Non-Destructive Tumor Aggregate Morphology and Viability Quantification at Cellular Resolution, During Development and in Response to Drug.

Cassandra L Roberge, David M Kingsley, Denzel E Faulkner, Charles J Sloat, Ling Wang, Margarida Barroso, Xavier Intes, David T Corr

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Cassandra L RobergeDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: roberc5@rpi.edu.
David M KingsleyDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: davemkingsley@gmail.com.
Denzel E FaulknerDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: faulkd@rpi.edu.
Charles J SloatDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: cjsloat97@gmail.com.
Ling WangDepartment of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, 12208, USA. Electronic address: wangl3@amc.edu.
Margarida BarrosoDepartment of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, 12208, USA. Electronic address: barrosm@amc.edu.
Xavier IntesDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: intesx@rpi.edu.
David T CorrDepartment of Biomedical Engineering, Rensselaer Polytechnic Institute, 110 Eighth St., Troy, NY 12180, USA. Electronic address: corrd@rpi.edu.
Rensselaer Polytechnic Institute · USAlbany Medical Center Hospital · US

Funding

Role of tumor heterogeneity on receptor engagementR01CA207725 · NCI · RENSSELAER POLYTECHNIC INSTITUTE · PI BARROSO, MARGARIDA, CORR, DAVID THOMAS · 2017 to 2021
$3.0M
In vivo Macroscopic Fluorescence Lifetime Molecular Optical ImagingR01CA250636 · NCI · RENSSELAER POLYTECHNIC INSTITUTE · PI BARROSO, MARGARIDA, INTES, XAVIER · 2020 to 2023
$2.9M
Endosome-mitochondria interactions in breast cancer cellsR01CA233188 · NCI · ALBANY MEDICAL COLLEGE · PI BARROSO, MARGARIDA · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA207725NCI NIH HHS R01 CA233188NCI NIH HHS R01 CA250636
6 · The paper itself

Abstract

Three-dimensional (3D) tissue-engineered in vitro models, particularly multicellular spheroids and organoids, have become important tools to explore disease progression and guide the development of novel therapeutic strategies. These avascular constructs are particularly powerful in oncological research due to their ability to mimic several key aspects of in vivo tumors, such as 3D structure and pathophysiologic gradients. Advancement of spheroid models requires characterization of critical features (i.e., size, shape, cellular density, and viability) during model development, and in response to treatment. However, evaluation of these characteristics longitudinally, quantitatively and non-invasively remains a challenge. Herein, Optical Coherence Tomography (OCT) is used as a label-free tool to assess 3D morphologies and cellular densities of tumor spheroids generated via the liquid overlay technique. We utilize this quantitative tool to assess Matrigel's influence on spheroid morphologic development, finding that the absence of Matrigel produces flattened, disk-like aggregates rather than 3D spheroids with physiologically-relevant features. Furthermore, this technology is adapted to quantify cell number within tumor spheroids, and to discern between live and dead cells, to non-destructively provide valuable information on tissue/construct viability, as well as a proof-of-concept for longitudinal drug efficacy studies. Together, these findings demonstrate OCT as a promising noninvasive, quantitative, label-free, longitudinal and cell-based method that can assess development and drug response in 3D cellular aggregates at a mesoscopic scale.

Indexed as

Spheroids, CellularTomography, Optical CoherenceCell Line, TumorTissue Engineeringcellular resolutionmorphologymulticellular tumor spheroidsoptical coherence tomographyviability

Identifiers

PMID33007490
PMCPMC7869529
OpenAlexW3090915052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.